The FDA knocked back MSB’s product for the treatment of a disease that has almost no other alternatives.
What makes anyone think they’ll approve it to treat large numbers of regular people with bad cases of COVID?
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-195
-
- There are more pages in this discussion • 198 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
-0.020(1.88%) |
Mkt cap ! $1.187B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.04 | $1.754M | 1.666M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 15249 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 114668 | 13 |
View Market Depth
| Last trade - 11.07am 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |